Randomised clinical trial: the safety and efficacy of long‐acting octreotide in patients with portal hypertension

Abstract

The absence of significant haemodynamic benefit, as well as the high frequency of severe adverse events associated with use of LAR, do not support the use of this agent in the treatment of portal hypertension.